Brachytherapy alone is enough for favorable intermediate-risk patients

RTOG 0232 was a large clinical trial conducted to determine whether low-dose-rate brachytherapy (LDR-BT) alone was of equal benefit compared to external beam radiation therapy with a brachytherapy boost (EBRT + LDR-BT) in intermediate-risk patients. … READ MORE …

Important updates to older radiotherapy studies from the ASTRO meeting

The following commentary provides updated data on two older but important studies of androgen deprivation therapy + radiation therapy in the treatment of locally advanced and progressive forms of prostate cancer. … READ MORE …

Low dose rate brachytherapy monotherapy across risk groups

New registry data from the Cleveland Clinic shows good oncological control with low dose rate brachytherapy (LDRBT) monotherapy, at least for low-risk and low  intermediate-risk groups. This is the first time I’ve seen LDRBT monotherapy data for higher-risk groups. … READ MORE …

A matched, case-control study of EBRT + PBRT vs brachytherapy

It would be all too easy to get the idea — from the title and abstract of a recently published study — that proton beam radiation therapy (PBRT) was more effective than permanent seed brachytherapy in the treatment of men with low- and some intermediate-risk prostate cancers. This would be a very inappropriate conclusion. … READ MORE …

EBRT for prostate cancer and increased risk for colon cancer?

A recent report by Rapiti et al. from the Geneva Cancer Registry documents a significant increase in risk for colon but not rectum cancer after earlier external beam radiotherapy (EBRT) for prostate cancer. While it is well known that radiotherapy can induce second cancers, there has been some controversy over the risk for second malignancies after irradiation for prostate cancer. … READ MORE …